Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.
Clarity Pharmaceuticals Ltd. reported a strong financial position with a cash balance of $288 million following a successful $203 million capital raise. The company is advancing its clinical trials, including the SECuRE trial for metastatic castration-resistant prostate cancer and the AMPLIFY trial for biochemical recurrence of prostate cancer, aiming for FDA approval of its diagnostic imaging agent.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.50 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. operates in the biotechnology industry, focusing on the development of radiopharmaceuticals for the treatment and diagnosis of serious diseases such as prostate cancer. The company is actively involved in clinical trials to advance its diagnostic and therapeutic products towards commercialization.
Average Trading Volume: 3,104,275
Technical Sentiment Signal: Buy
Current Market Cap: A$1.36B
Learn more about CU6 stock on TipRanks’ Stock Analysis page.